Key statistics
As of last trade Novocure Ltd (038:BER) traded at 16.80, -25.62% below its 52-week high of 22.58, set on May 20, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 16.33 |
---|---|
High | 17.05 |
Low | 16.33 |
Bid | 16.53 |
Offer | 16.82 |
Previous close | 16.39 |
Average volume | 83.67 |
---|---|
Shares outstanding | 108.20m |
Free float | 98.19m |
P/E (TTM) | -- |
Market cap | 1.85bn USD |
EPS (TTM) | -1.39 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 18:37 GMT.
More ▼
Press releases
- Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma
- FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
- Novocure Appoints Christoph Brackmann as Chief Financial Officer
- Novocure Reports Third Quarter 2024 Financial Results
- Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors
- FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
- Novocure to Report Third Quarter 2024 Financial Results
- Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy
- Novocure Announces Planned CEO Transition
- Novocure to Participate in 2024 Wells Fargo Healthcare Conference
More ▼